Načítá se...
Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis
INTRODUCTION: The Janus kinase (JAK)1/2 inhibitor ruxolitinib provides rapid, sustained and often dramatic benefits to patients with myelofibrosis, inducing spleen shrinkage and ameliorating symptoms, and improves survival. However, the drug has little effect on the underlying bone marrow fibrosis o...
Uloženo v:
| Vydáno v: | Expert Opin Orphan Drugs |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7577425/ https://ncbi.nlm.nih.gov/pubmed/33094033 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21678707.2019.1664900 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|